METiS Pharmaceuticals

What METiS Pharmaceuticals does

METiS Pharmaceuticals (剂泰科技（北京）股份有限公司) is an AI-driven nanomedicine company founded in 2020 in Beijing, China, developing AI-powered platforms for nanoparticle drug formulation and targeted delivery. The company's core technology stack includes two proprietary platforms: AiLNP, an AI Nano Delivery System Design Platform that uses molecular dynamics simulations of lipid nanoparticle (LNP) endosomal escape combined with quantum mechanics calculations; and NanoForge, launched in September 2025 and positioned as the world's first AI nanoparticle delivery platform for designing and optimizing nanocarriers across therapeutic applications.

The company's clinical pipeline consists of MTS-004, China's first AI-enabled formulation drug to complete Phase III clinical trials for the treatment of Probable Progressive Angiopathy (PBA) / phenylbutyric acid-related indications, and MTS-105, a hepatocellular carcinoma treatment candidate that received US FDA Orphan Drug Designation in December 2025. The company serves the pharmaceutical and healthcare verticals, targeting unmet medical needs in oncology and neonatal care. Its clinical-stage assets and government-backed R&D partnerships — including a co-established Beijing Key Laboratory with the National Nanoscience Center (February 2026) — support an enterprise-grade regulatory and commercial pathway.

METiS has raised over $350 million cumulatively from institutional investors including PICC PE, China Life, Sequoia Capital China, Luminous Ventures (former Lightspeed China Partners), 5Y Capital, Frees Fund, HSG, and CICC Capital, among others. The company operates with 51-100 employees and is pursuing a Hong Kong IPO (CSRC clearance received March 2026, as MRTIS TechBio (Beijing) Co., Ltd., planning up to 273 million shares). Its revenue model is one-time license based on drug development and eventual commercialization; the company is currently pre-revenue with no approved products.

Name

METiS Pharmaceuticals

Legal name

剂泰科技（北京）股份有限公司

Website

https://metispharmaceuticals.cn

Company type

Private

Founded year

2020

Operating status

Ipo

Headcount range

51–100 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug development and commercialization: METiS Pharmaceuticals generates revenue through the development and eventual commercialization of AI-designed nano drug candidates. The company has advanced pipeline candidates including MTS-004 (Phase III completed) and MTS-105 (FDA orphan drug designation). The company is pursuing an HK IPO, indicating a pathway to public markets for commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

METiS Pharmaceuticals develops AI-driven nanoparticle drug delivery systems and clinical-stage drug formulations. Its proprietary platforms AiLNP and NanoForge use advanced algorithms, quantum mechanics, and molecular dynamics simulations to design lipid nanoparticle (LNP) delivery systems for targeted therapeutics. The company advances drug candidates through clinical trials, including MTS-004 (China's first AI-enabled formulation drug to complete Phase III) for premature birth complications and MTS-105 (FDA orphan drug designated) for hepatocellular carcinoma.

Product overview

METiS Pharmaceuticals operates as an AI-driven nanomedicine company with two interconnected platforms: the AiLNP platform for AI-powered nanoparticle delivery system design (featuring molecular dynamics simulations for LNP endosomal escape optimization) and NanoForge, positioned as the world's first AI nanoparticle delivery platform launched in 2025. The company's clinical pipeline includes MTS-004 (China's first AI-enabled formulation drug completing Phase III trials for PBA treatment) and MTS-105 (FDA-designated orphan drug for hepatocellular carcinoma). The platforms and pipeline products form an integrated AI-driven drug discovery and nanomedicine development ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• AiLNP: AI Nano-Delivery System Design Platform for LNP endosomal escape molecular dynamics simulation and nano-delivery system optimization.
• NanoForge

Products and services

• AiLNP (AI Nanoparticle Delivery System Design Platform)

Quantifiable outcome

• First AI-enabled formulation drug in China to complete Phase III trials (MTS-004)
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

One partnership is on record.

• National Nanoscience Center (国家纳米科学中心)coreStrategic or Co-development Partner · 4 February 2026METiS Pharmaceuticals co-established a Beijing Key Laboratory (北京市重点实验室) with the National Nanoscience Center. This strategic R&D partnership focuses on nano innovation and represents a core collaboration with a leading Chinese government research institution.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• XtalPi: Chinese AI-driven drug discovery and crystal engineering platform combining physics-based simulation with AI. Closest comparable as a China-based AI pharma platform with overlapping quantum/molecular dynamics foundations; XtalPi was also an early METiS investor.
• Insitro: US-based AI-driven drug discovery company combining ML, high-throughput biology, and generative models. Comparable as an AI-native platform company developing proprietary therapeutic candidates through internal pipeline.
• Recursion Pharmaceuticals: AI-driven drug discovery platform using high-throughput experimentation and foundation models. Comparable as a publicly-listed AI drug discovery company with internal pipeline assets, providing a benchmark for AI-pharma economics.
• Schrödinger: Computational chemistry and AI platform combining physics-based simulation with ML for drug discovery. Directly comparable on the physics-plus-AI methodology METiS uses for formulation and delivery design.
• Acuitas Therapeutics: LNP delivery technology specialist whose lipid systems underpin multiple approved mRNA therapeutics. Closest pure-play LNP comparator and a key potential competitor or partner for METiS's AiLNP platform.
• AbCellera Biologics: AI/ML-enabled antibody discovery platform with internal pipeline assets. Comparable as a technology-first biotech monetizing both internal pipeline and platform partnerships.
• Bota Bio: Chinese AI-driven biomanufacturing and synthetic biology company. Comparable as a China-based AI biotech combining computational biology with industrial-scale bioprocess development.

Emerging players

• Arcturus Therapeutics: Clinical-stage LNP and mRNA therapeutics company with late-stage assets. Comparable as a focused LNP-delivery therapeutic developer, though more mature on clinical assets than METiS.
• Generate Biomedicines: Generative AI biology platform designing novel protein therapeutics. Comparable as a generative-AI-native biotech developing internal therapeutic candidates from a platform foundation.

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company combining DeepMind's AlphaFold with pharma partnerships. A broad incumbent operating at much larger scale, representing both a competitive threat and a strategic benchmark for AI-pharma commercialization.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds8 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about METiS Pharmaceuticals